X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BVX-0918A, BioVaxys’s cancer vaccines are created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic.
Lead Product(s): BVX-0918
Therapeutic Area: Oncology Product Name: BVX-0918
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Biovaxys
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
Bio Elpida has completed the technology process transfer of BVX-0918A with BioVaxys and started the development phase using a Quality by Design (“QbD”) approach which includes establishing the control methods and manufacturing process development.
Lead Product(s): BVX-0918A
Therapeutic Area: Oncology Product Name: BVX-0918A
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Biovaxys
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 17, 2021
Details:
BioVaxys has signed the definitive exclusive bioproduction agreement with BioElpida, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys’ vaccine candidate for Stage III/Stage IV ovarian cancer.
Lead Product(s): BVX-0918A
Therapeutic Area: Oncology Product Name: BVX-0918A
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Biovaxys
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
